Pursuant to Regulation 22 of the Misuse of Drugs Regulations 1977, I, Michael Haynes, Manager, Medicines Control, Medsafe, Ministry of Health, acting under delegated authority from the Minister of Health, hereby make the following approval:

That lisdexamfetamine (a controlled drug described in Part 2 of Schedule 2 of the Misuse of Drugs Act 1975) may be prescribed or supplied or administered by the classes of persons described, and in the circumstances set out in the following Schedule.

Schedule

Prescribing

From 20 December 2022:

The following class of persons (“vocational medical practitioners”) may prescribe lisdexamfetamine products for a patient under their care for the corresponding conditions:

• medical practitioners with a vocational scope of practice of paediatrics or psychiatry, registered with the Medical Council of New Zealand under the Health Practitioners Competence Assurance Act 2003, for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Any other medical practitioner registered with the Medical Council of New Zealand (“registered medical practitioner”), or nurse practitioner registered with the Nursing Council of New Zealand practising within their area of practice (“nurse practitioner”), may only prescribe lisdexamfetamine products when acting on the written recommendation of one of the vocational medical practitioners described above, for the conditions specified.

Supply

From 20 December 2022:

The following class of persons may supply lisdexamfetamine products in the following circumstances:

Any pharmacist registered with the Pharmacy Council of New Zealand under the Health Practitioners Competence Assurance Act 2003, in the course of his or her employment as a pharmacist, may supply lisdexamfetamine products pursuant to a prescription issued by:

• a registered medical practitioner with a vocational scope of practice of paediatrics, or psychiatry, when prescribing for the conditions specified in this Schedule; or
• any other registered medical practitioner or nurse practitioner, when acting on the written recommendation of one of the vocational medical practitioners specified in this Schedule, with the recommendation endorsed on the prescription.

Administration

From 20 December 2022:

Any person who is caring for a patient, for whom a lisdexamfetamine product has been prescribed by any of the medical practitioners or nurse practitioners described in this Schedule, may administer the product to that patient in accordance with the prescribed directions for use.

Dated at Wellington this 20th day of December 2022.

MICHAEL HAYNES, Manager, Medicines Control, Medsafe, Ministry of Health.